The Enhanced Recovery After Surgery (ERAS) protocol promotes multimodal analgesia to optimize postoperative pain control and reduce opioid consumption. To mitigate the risks of opioid-induced respiratory depression and postoperative ileus, ERAS incorporates alternative strategies, including continuous lidocaine infusion. However, excessive administration of lidocaine can cause local anesthetic systemic toxicity (LAST), potentially leading to adverse central nervous system and cardiovascular effects such as respiratory depression, seizures, coma, arrhythmia, and cardiac arrest.

This study aims to develop a pharmacokinetic model of lidocaine infusion using a one-compartment approach based on differential equations. Assuming a half-life of 2 hours and a maximum safe plasma concentration of 5 mg/kg, the model predicts lidocaine concentrations over time, estimates the optimal discontinuation point, and calculates the additional allowable bupivacaine dose for a transversus abdominis plane (TAP) block at the end of surgery to minimize the risk of LAST.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript